

NEXT GENERATION SEQUENCING AT AROS



AROS has completed the first phase of implementing Next Generation Sequencing (NGS), and is now ready to launch these services.

NGS services at AROS are characterized by the following:

The same high laboratory standards

As with many other types of genomic analyses, quality and efficiency within NGS is largely dependent on high-precision laboratory work during the sample preparation phase. Our NGS customers will benefit from AROS's proven track record of the highest quality standards that we have established and maintained over the previous 10 years (we have built the most experienced team of scientists and technicians in the industry). We are dedicated to generating the best quality data set possible for each project that is processed at AROS.

A focus on the individual and specific needs of each customer

Even with the increasing number of different microarrays that are available, typically there would be 2-3 different alternatives to choose from at the most. NGS is a much more versatile platform, with many more parameters to consider, e.g. targeting methods, library preparation, number of reads and coverage etc. For these reasons we feel that it is crucial that there is a close and open dialogue between us as the service provider, and the customer. Our scientists are committed to maintaining a complete overview of the NGS marketplace, including the latest technologies available, the newest protocols, and in general keep up-to-date with the most current knowledge in this field. At AROS, our scientists will assist you in defining the various possible / alternative approaches, the pros & cons of each, and help to identify the best design to "fit" each project, based on sample material, data / application requirements, budget etc. Although NGS has many advantages, the best approach for many projects could be a combination amongst others of NGS, microarray analysis and targeted validation. With AROS, you will benefit from our broad knowledge base and experience across a whole range of genomic technologies.

At launch, our core offerings will be centered around the main applications within transcriptome and DNA sequencing on Illumina's sequencing platforms. Please feel free to discuss any kind of NGS need that you have with us, as we will continuously widen and develop our portfolio of NGS offerings.